<p>藥明康德（NASDAQ:PAHC - 獲取免費報告）在週五發佈的研究報告中被 StockNews.com 的股票研究分析師從 “買入” 評級下調至 “持有” 評級。</p>
<p>獲取 <strong>藥明康德</strong> 的提醒：</p>
<p>其他一些研究分析師最近也對 PAHC 發表了評論。巴克萊將藥明康德的目標價從 20.00 美元上調至 22.00 美元，並在 2 月 10 日的研究報告中給予該股票 “減持” 評級。摩根士丹利將藥明康德的目標價從 20.00 美元上調至 25.00 美元，並在 12 月 17 日的報告中給予該公司 “持平” 評級。兩位分析師對該股票給予了賣出評級，三位分析師則給予了持有評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，平均目標價為 21.00 美元。</p>
<p><strong>獲取我們最新的藥明康德股票分析</strong></p>
<h2>藥明康德股票表現</h2>
<p>週五，NASDAQ PAHC 的股票上漲了 0.33 美元，達到 23.64 美元。該股票的交易量為 339,958 股，而其平均交易量為 253,645 股。藥明康德的年低為 11.98 美元，年高為 26.55 美元。該公司的債務與股本比率為 2.99，速動比率為 1.37，流動比率為 3.20。該股票的市值為 9.5749 億美元，市盈率為 49.25，市盈增長比率為 0.45，貝塔值為 0.52。該公司的 50 日移動平均價格為 22.47 美元，200 日移動平均價格為 22.48 美元。</p>
<p>藥明康德（NASDAQ:PAHC - 獲取免費報告）最近在 2 月 5 日發佈了季度財報。該公司報告每股收益為 0.54 美元，超出分析師一致預期的 0.40 美元，超出幅度為 0.14 美元。藥明康德的股本回報率為 25.35%，淨利潤率為 1.75%。研究分析師平均預測藥明康德在當前財政年度的每股收益將達到 1.95 美元。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金最近買入和賣出了 PAHC 的股票。Point72 Asia Singapore Pte. Ltd.在第四季度購買了藥明康德的新股份，價值約 29,000 美元。Lazard Asset Management LLC 在第四季度將其在藥明康德的股份增加了 2,739.7%。Lazard Asset Management LLC 現在擁有 1,647 股該公司的股票，價值 34,000 美元，此前在上個季度又購買了 1,589 股。Quantbot Technologies LP 在第三季度購買了藥明康德的新股份，價值約 70,000 美元。Virtus Fund Advisers LLC 在第四季度購買了藥明康德的新股份，價值約 69,000 美元。最後，Aquatic Capital Management LLC 在第四季度購買了藥明康德的新股份，價值約 69,000 美元。99.34% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於藥明康德</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司在美國、以色列、巴西、愛爾蘭及國際上經營動物健康和礦物營養業務。它通過三個部門運營：動物健康、礦物營養和性能產品。該公司開發、製造和銷售各種食品和伴侶動物的產品，包括家禽、豬、肉牛和奶牛、水產養殖和狗。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過藥明康德</li>
<li>消費品股票解析</li>
<li>Myers Industries 是否準備好突破？</li>
<li>投資黃金股票的方式和原因</li>
<li>BigBear.ai 的 25% 暴跌是虛驚一場還是拋售？</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>博通確認其人工智能前景：股票即將創下新高</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PAHC

<p>Phibro Animal Health（納斯達克代碼：PAHC）被 StockNews.com 從 “買入” 評級下調至 “持有” 評級。其他分析師的觀點不一，巴克萊將其目標價上調至 22 美元，摩根士丹利則上調至 25 美元。該股票目前交易價格為 23.64 美元，市值為 9.5749 億美元。Phibro 報告每股收益為 0.54 美元，超出預期。機構投資者持有 99.34% 的股份。分析師預測本財年的每股收益為 1.95</p>

<p>Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by equities research analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Friday.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:PAHC - 獲取免費報告）在週五發佈的研究報告中被 StockNews.com 的股票研究分析師從 “買入” 評級下調至 “持有” 評級。</p>
</div><p>Get <strong>Phibro Animal Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>藥明康德</strong> 的提醒：</p>
</div><p>A number of other research analysts also recently commented on PAHC. Barclays upped their price objective on Phibro Animal Health from $20.00 to $22.00 and gave the stock an &#34;underweight&#34; rating in a research note on Monday, February 10th. Morgan Stanley upped their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an &#34;equal weight&#34; rating in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Hold&#34; and an average price target of $21.00.</p>
<div class="lb-trans"><p>其他一些研究分析師最近也對 PAHC 發表了評論。巴克萊將藥明康德的目標價從 20.00 美元上調至 22.00 美元，並在 2 月 10 日的研究報告中給予該股票 “減持” 評級。摩根士丹利將藥明康德的目標價從 20.00 美元上調至 25.00 美元，並在 12 月 17 日的報告中給予該公司 “持平” 評級。兩位分析師對該股票給予了賣出評級，三位分析師則給予了持有評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，平均目標價為 21.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Phibro Animal Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的藥明康德股票分析</strong></p>
</div><h2>Phibro Animal Health Stock Performance</h2>
<div class="lb-trans"><h2>藥明康德股票表現</h2>
</div><p>Shares of NASDAQ PAHC traded up $0.33 during trading on Friday, reaching $23.64. The stock had a trading volume of 339,958 shares, compared to its average volume of 253,645. Phibro Animal Health has a one year low of $11.98 and a one year high of $26.55. The company has a debt-to-equity ratio of 2.99, a quick ratio of 1.37 and a current ratio of 3.20. The stock has a market cap of $957.49 million, a PE ratio of 49.25, a P/E/G ratio of 0.45 and a beta of 0.52. The firm's 50 day moving average price is $22.47 and its two-hundred day moving average price is $22.48.</p>
<div class="lb-trans"><p>週五，NASDAQ PAHC 的股票上漲了 0.33 美元，達到 23.64 美元。該股票的交易量為 339,958 股，而其平均交易量為 253,645 股。藥明康德的年低為 11.98 美元，年高為 26.55 美元。該公司的債務與股本比率為 2.99，速動比率為 1.37，流動比率為 3.20。該股票的市值為 9.5749 億美元，市盈率為 49.25，市盈增長比率為 0.45，貝塔值為 0.52。該公司的 50 日移動平均價格為 22.47 美元，200 日移動平均價格為 22.48 美元。</p>
</div><p>Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. On average, research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:PAHC - 獲取免費報告）最近在 2 月 5 日發佈了季度財報。該公司報告每股收益為 0.54 美元，超出分析師一致預期的 0.40 美元，超出幅度為 0.14 美元。藥明康德的股本回報率為 25.35%，淨利潤率為 1.75%。研究分析師平均預測藥明康德在當前財政年度的每股收益將達到 1.95 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds have recently bought and sold shares of PAHC. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $29,000. Lazard Asset Management LLC boosted its stake in shares of Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after acquiring an additional 1,589 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $70,000. Virtus Fund Advisers LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. Finally, Aquatic Capital Management LLC bought a new stake in shares of Phibro Animal Health during the 4th quarter worth about $69,000. 99.34% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金最近買入和賣出了 PAHC 的股票。Point72 Asia Singapore Pte. Ltd.在第四季度購買了藥明康德的新股份，價值約 29,000 美元。Lazard Asset Management LLC 在第四季度將其在藥明康德的股份增加了 2,739.7%。Lazard Asset Management LLC 現在擁有 1,647 股該公司的股票，價值 34,000 美元，此前在上個季度又購買了 1,589 股。Quantbot Technologies LP 在第三季度購買了藥明康德的新股份，價值約 70,000 美元。Virtus Fund Advisers LLC 在第四季度購買了藥明康德的新股份，價值約 69,000 美元。最後，Aquatic Capital Management LLC 在第四季度購買了藥明康德的新股份，價值約 69,000 美元。99.34% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Phibro Animal Health</h2>
<div class="lb-trans"><h2>關於藥明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.</p>
<div class="lb-trans"><p>藥明康德公司在美國、以色列、巴西、愛爾蘭及國際上經營動物健康和礦物營養業務。它通過三個部門運營：動物健康、礦物營養和性能產品。該公司開發、製造和銷售各種食品和伴侶動物的產品，包括家禽、豬、肉牛和奶牛、水產養殖和狗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Phibro Animal Health</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Is Myers Industries Poised for a Breakout?</li>
<li>The How and Why of Investing in Gold Stocks</li>
<li>Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過藥明康德</li>
<li>消費品股票解析</li>
<li>Myers Industries 是否準備好突破？</li>
<li>投資黃金股票的方式和原因</li>
<li>BigBear.ai 的 25% 暴跌是虛驚一場還是拋售？</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>博通確認其人工智能前景：股票即將創下新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phibro Animal Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Phibro Animal Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藥明康德並不在名單上。</p>
</div><p>While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Phibro Animal Health (NASDAQ:PAHC) Cut to "Hold" at StockNews.com

藥明康德動物健康（NASDAQ:PAHC）在 StockNews.com 被降級為 “持有” 評級